Robert Kleiman, MD

How new technology can impact cardiac imaging in oncology clinical trials and have broader implications for patient safety.

Explore the growing interest in better understanding the potential for cardiovascular complications associated with cancer therapies.

An updated release to the ICH E14 Guidance could indicate that data be used to replace a TQT trial for regulatory submission and review. The result of such a change would be a reduction in development time and costs for biopharma companies.

Results from an analysis of oncology trials suggest that many patients who are excluded from participation in clinical trials due to an elevated ECG machine-generated QTc measurement may actually have been eligible for study participation.